RC148 

RC148 is a humanized IgG1 bispecific antibody targeting VEGF and PD-1. RC148 blocks PD-1-PD-L1 and VEGF-VEGFR interactions, triggers VEGF-dependent enhanced PD-1 binding, enables VEGF crosslinking, and inhibits PD-1-mediated immunosuppression. RC148 can be used for the research of metastatic gastric/gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and metastatic breast cancer^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

RC148 inhibits VEGF-VEGFR and PD-1-PD-L1 binding, suppresses human umbilical vein endothelial cell growth and migration, and efficiently activates T cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

29126  [NCBI] & 7422  [NCBI]

Q9NZQ7 & P15692

PD-1 & VEGF

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

167.34 kDa

Liquid

Colorless to light yellow

N/A

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Human PD1 Protein, His Tag can bind RC148. The EC₅₀ for this effect is 148.6 ng/mL.
• 
  Immobilized Human VEGF165 Protein, hFc Tag can bind RC148. The EC₅₀ for this effect is 106 ng/mL.

• [1]. Fang JM, et al. Abstract 2734: RC148, a novel bispecific antibody targeting PD-1 and VEGF for cancer immunotherapy. Cancer Res. 2024 Mar 24;84(6_Supplement);2734.

  [2]. Wang JY, et al. Efficacy and safety of disitamab vedotin in combination with RC148 versus albumin-bound paclitaxel ± toripalimab for patients with HR-negative HER2-low-expressing unresectable locally advanced or metastatic breast cancer: An open-label, randomized, controlled phase II study. J Clin Oncol. 2025 May 28; 43(16_suppl):TPS1139.